Key facts
- It has raised $16.5M across 1 recorded rounds; the latest was Seed Round ($3.0M) in May 2019.
- Notable investors include Village Global, Balaji Srinivasan, Elad Gil, WndrCo, Day One Ventures — 29 tracked in total.
- Orchid Health has filed 1 Form D with the SEC, most recently Jul 2019 ($3.0M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Orchid Health
Funding rounds
1 roundsAbout Orchid Health
Developer of a home-based genetic test kit designed to help determine the genetic impact on a child's health. The company's platform provides a comprehensive analysis of genomic information from saliva samples and consolidates multiple assays into one by calculating genetic risk scores, enabling couples to safely and naturally mitigate genetic risk for the baby.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 50
- Website
- orchidhealth.com/
- Ownership
- Privately Held (backing)
Orchid Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orchid Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orchid Health in its N-PORT filings yet. We sweep new filings monthly.